189 related articles for article (PubMed ID: 24924589)
1. Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.
Gallagher SJ; Mijatov B; Gunatilake D; Gowrishankar K; Tiffen J; James W; Jin L; Pupo G; Cullinane C; McArthur GA; Tummino PJ; Rizos H; Hersey P
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1126-37. PubMed ID: 24924589
[TBL] [Abstract][Full Text] [Related]
2. NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.
Hishiki K; Akiyama M; Kanegae Y; Ozaki K; Ohta M; Tsuchitani E; Kaito K; Yamada H
Leuk Res; 2018 Nov; 74():57-63. PubMed ID: 30300821
[TBL] [Abstract][Full Text] [Related]
3. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts.
Klein K; Kabala PA; Grabiec AM; Gay RE; Kolling C; Lin LL; Gay S; Tak PP; Prinjha RK; Ospelt C; Reedquist KA
Ann Rheum Dis; 2016 Feb; 75(2):422-9. PubMed ID: 25467295
[TBL] [Abstract][Full Text] [Related]
4. BET bromodomain proteins are required for glioblastoma cell proliferation.
Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
[TBL] [Abstract][Full Text] [Related]
5. Hmgb1 inhibits Klotho expression and malignant phenotype in melanoma cells by activating NF-κB.
Xie B; Cao K; Li J; Chen J; Tang J; Chen X; Xia K; Zhou X; Cheng Y; Zhou J; Xie H
Oncotarget; 2016 Dec; 7(49):80765-80782. PubMed ID: 27779100
[TBL] [Abstract][Full Text] [Related]
6. BET inhibitor suppresses melanoma progression
Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
[No Abstract] [Full Text] [Related]
7. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes.
Xiao Y; Liang L; Huang M; Qiu Q; Zeng S; Shi M; Zou Y; Ye Y; Yang X; Xu H
Rheumatology (Oxford); 2016 Jan; 55(1):173-84. PubMed ID: 26324948
[TBL] [Abstract][Full Text] [Related]
8. Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling.
Heinemann A; Cullinane C; De Paoli-Iseppi R; Wilmott JS; Gunatilake D; Madore J; Strbenac D; Yang JY; Gowrishankar K; Tiffen JC; Prinjha RK; Smithers N; McArthur GA; Hersey P; Gallagher SJ
Oncotarget; 2015 Aug; 6(25):21507-21. PubMed ID: 26087189
[TBL] [Abstract][Full Text] [Related]
9. NF-kappaB activation in melanoma.
Ueda Y; Richmond A
Pigment Cell Res; 2006 Apr; 19(2):112-24. PubMed ID: 16524427
[TBL] [Abstract][Full Text] [Related]
10. I-BET151 selectively regulates IL-6 production.
Barrett E; Brothers S; Wahlestedt C; Beurel E
Biochim Biophys Acta; 2014 Sep; 1842(9):1549-55. PubMed ID: 24859008
[TBL] [Abstract][Full Text] [Related]
11. Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells.
Yang J; Richmond A
Cancer Res; 2001 Jun; 61(12):4901-9. PubMed ID: 11406569
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-21 regulates the ERK/NF-κB signaling pathway to affect the proliferation, migration, and apoptosis of human melanoma A375 cells by targeting SPRY1, PDCD4, and PTEN.
Mao XH; Chen M; Wang Y; Cui PG; Liu SB; Xu ZY
Mol Carcinog; 2017 Mar; 56(3):886-894. PubMed ID: 27533779
[TBL] [Abstract][Full Text] [Related]
13. Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth.
Niu N; Shao R; Yan G; Zou W
J Biol Chem; 2016 Dec; 291(52):26647-26657. PubMed ID: 27821592
[TBL] [Abstract][Full Text] [Related]
14. The BET bromodomain inhibitor i-BET151 impairs ovarian cancer metastasis and improves antitumor immunity.
Liu A; Fan D; Wang Y
Cell Tissue Res; 2018 Dec; 374(3):577-585. PubMed ID: 30182276
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma.
Tseng HY; Dreyer J; Emran AA; Gunatilake D; Pirozyan M; Cullinane C; Dutton-Regester K; Rizos H; Hayward NK; McArthur G; Hersey P; Tiffen J; Gallagher S
Int J Cancer; 2020 Oct; 147(8):2176-2189. PubMed ID: 32249419
[TBL] [Abstract][Full Text] [Related]
16. BET bromodomain inhibition suppresses transcriptional responses to cytokine-Jak-STAT signaling in a gene-specific manner in human monocytes.
Chan CH; Fang C; Yarilina A; Prinjha RK; Qiao Y; Ivashkiv LB
Eur J Immunol; 2015 Jan; 45(1):287-297. PubMed ID: 25345375
[TBL] [Abstract][Full Text] [Related]
17. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness.
Kunz M; Hartmann A; Flory E; Toksoy A; Koczan D; Thiesen HJ; Mukaida N; Neumann M; Rapp UR; Bröcker EB; Gillitzer R
Am J Pathol; 1999 Sep; 155(3):753-63. PubMed ID: 10487833
[TBL] [Abstract][Full Text] [Related]
18. BET bromodomain inhibition reduces maturation and enhances tolerogenic properties of human and mouse dendritic cells.
Schilderink R; Bell M; Reginato E; Patten C; Rioja I; Hilbers FW; Kabala PA; Reedquist KA; Tough DF; Tak PP; Prinjha RK; de Jonge WJ
Mol Immunol; 2016 Nov; 79():66-76. PubMed ID: 27710838
[TBL] [Abstract][Full Text] [Related]
19. MED27 promotes melanoma growth by targeting AKT/MAPK and NF-κB/iNOS signaling pathways.
Tang R; Xu X; Yang W; Yu W; Hou S; Xuan Y; Tang Z; Zhao S; Chen Y; Xiao X; Huang W; Guo W; Li M; Deng W
Cancer Lett; 2016 Apr; 373(1):77-87. PubMed ID: 26797421
[TBL] [Abstract][Full Text] [Related]
20. Involvement of nuclear factor-kB activation through RhoA/Rho-kinase pathway in LPS-induced IL-8 production in human cervical stromal cells.
Shimizu S; Tahara M; Ogata S; Hashimoto K; Morishige K; Tasaka K; Murata Y
Mol Hum Reprod; 2007 Mar; 13(3):181-7. PubMed ID: 17227815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
